Archive for the ‘UCLA spinoffs’ Category

Bioenergy Expert Joins Ceres (UCLA) in Brazil (12/20/2010)

December 20, 2010

Ceres develops biopower energy crops and cellulosic biofuels. Dr. Richard Flavell, the company’s Chief Scientific Officer, is also an Adjunct Professor of Molecular, Celluar and Developmental Biology at UCLA.

From the company’s press release:
Ceres, a leading developer of bioenergy crops, has appointed William Burnquist as the general manager of its operations in Brazil. An experienced leader in Brazil’s sugarcane and ethanol sector, Burnquist will administer the day-to-day activities of the company’s subsidiary, Ceres Sementes do Brasil Ltda., including local seed production and Ceres’ network of sweet sorghum trials. read full press release

Fibron (UCLA) on Innovative Aniline Nanostructures (12/10/2010)

December 17, 2010

Fibron Technologies specializes in processable and nanostructured conducting polymers. Among the company’s co-founders are UCLA Chemistry Professor Richard B. Kaner, Ph.D. and two graduates from his laboratory.

From the company’s blog:
Henry Tran and UCLA professor Richard Kaner, two of Fibron Technologies’ founders, authored the article ‘The Oxidation of Aniline to Produce “Polyaniline”: A Process Yielding Many Different Nanoscale Structures’ which is being highlighted as a ‘Hot Article’ for the Journal of Materials Chemistry. This article is available for free until January 6, 2011. read full blog entry

Prometheus (UCLA) and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis (12/8/2010)

December 17, 2010

Prometheus Laboratories is a biotechnology company that develops diagnostic and therapeutic products. The company has been licensing technology from UCLA since 1996.

From the company’s press release:
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The addition of this mutational analysis services agreement broadens Bayer’s oncology-focused molecular and pathway activation profiling collaboration with Prometheus to include comprehensive mutational analyses. The expanded information derived from this agreement has the potential to improve patient stratification in clinical studies and accelerate the development of novel oncology diagnostic and therapeutic products. read full press releaes

Prometheus Laboratories (UCLA) and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis (12/8/2010)

December 13, 2010

Prometheus Laboratories is a biotechnology company that develops diagnostic and therapeutic products. The company has been licensing technology from UCLA since 1996.

From the company’s press release:
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The addition of this mutational analysis services agreement broadens Bayer’s oncology-focused molecular and pathway activation profiling collaboration with Prometheus to include comprehensive mutational analyses. The expanded information derived from this agreement has the potential to improve patient stratification in clinical studies and accelerate the development of novel oncology diagnostic and therapeutic products. read full press release

Prometheus Laboratories (UCLA) Extends Distribution Agreement for ENTOCORT® EC (Budesonide) Capsules With AstraZeneca LP (11/30/2010)

December 13, 2010

Prometheus Laboratories is a biotechnology company that develops diagnostic and therapeutic products. The company has been licensing technology from UCLA since 1996.

From the company’s press release:
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today that it has extended its distribution agreement with AstraZeneca LP for the exclusive marketing, sales and distribution of ENTOCORT® EC (budesonide) Capsules in the United States until December 31, 2011. ENTOCORT EC is the only FDA-approved drug for the induction and maintenance of clinical remission in mild to moderate Crohn’s disease involving the ileum and/or the ascending colon. ENTOCORT EC is indicated for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon (up to 8 weeks with repeated 8-week courses as necessary for recurring episodes of active disease), and the maintenance of clinical remission of mild to moderate Crohn’s disease involving the ileum and/or the ascending colon for up to 3 months. Clinical remission is defined as a Crohn’s Disease Activity Index (CDAI) score of ≤150. read full press release

Ceres (UCLA) Survey: Growers Ready to Put Marginal Lands to Better Use (11/23/2010)

December 13, 2010

Ceres develops biopower energy crops and cellulosic biofuels. Dr. Richard Flavell, the company’s Chief Scientific Officer, is also an Adjunct Professor of Molecular, Celluar and Developmental Biology at UCLA.

From the company’s press release:
Energy crop developer Ceres, Inc. reports that growers are ready and willing to produce biomass for biopower and advanced biofuels, and have the land to do so. read full press release

Gevo’s (Caltech, UCLA) Isobutanol Secures EPA Registration (11/11/2010)

November 13, 2010

Gevo, founded in 2005, is developing capital efficient biorefinery systems. Among its four co-founders are Prof. Frances Arnold from Caltech and Prof. James C. Liao from UCLA.

From the company’s press release:
Gevo, Inc., a privately held renewable chemicals and advanced biofuels company, announced today that it received notification that its isobutanol had successfully cleared registration with the U.S. EPA as a fuel additive. Gevo’s isobutanol is the first isobutanol to be listed in the EPA’s Fuel Registration Directory and is now approved for blending with gasoline. read full press release

AutoESL (UCLA) Partners with Convey (11/9/2010)

November 13, 2010

AutoESL provides high level synthesis for FPGAs and ASICs. The company was founded in 2006 by UCLA Professor Jason Cong, Ph.D. and UCLA Computer Science Researchers Yiping Fan, Ph.D. and Zhiru Zhang, Ph.D.

From Convey Computer’s press release:
Convey Computer™ Corporation announced today five new technology and business partnerships that extend application availability for its hybrid-core computing platforms. The solutions provided by these partners help Convey deliver even greater performance, functionality, and choice to their customers.

Technologies such as network-attached storage, personality development tools, and speech recognition solutions are now available for Convey’s hybrid-core platforms. The new Convey partners include Panasas, AutoESL, Impulse, Jacquard Computing, and Voci Technologies. read full press release

ArmaGen (UCLA) Re-Engineers Erythropoietin for Stroke (11/5/2010)

November 9, 2010

ArmaGen provides platform technology solutions to the ‘blood-brain barrier’ problem. The company was founded in 2004 by Dr. William Pardridge, Professor of Medicine and Endocrinology at UCLA.

ArmaGen re-engineers erythropoietin for stroke. Erythropoietin (EPO) is a potent neuroprotective agent, which could be developed for treatment of acute stroke. However, EPO does not cross the blood-brain barrier (BBB), and the BBB is intact in the early hours after stroke when neuroprotection is still possible. AGT-115 is a re-engineered form of human EPO that crosses the BBB via receptor-mediated transport. EPO is fused to a genetically engineered monoclonal antibody (MAb) against the human insulin receptor (HIR). read more

Bruin Biometrics (UCLA) Announces Award (11/3/2010)

November 4, 2010

Bruin Biometrics (BBI) is a wireless health technology company developing devices, software, and solutions. The company exclusively licenses its platform technology from the Regents of the State of California and UCLA.

Bruin Biometrics announces an award of $244K for a therapeutic discovery project grant from the Department of the Treasury. Funds will be used to support continued research and development costs.